{"DataElement":{"publicId":"2431555","version":"2.1","preferredName":"Nottingham Mitotic Count Grade","preferredDefinition":"A score indicating how many dividing cells are present which is representative of the speed of how fast tumor cells are growing and dividing reported using the Nottingham Prognostic Index for grade of breast cancer.","longName":"NOTTH_MIT_CT_GD","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2431349","version":"1","preferredName":"Nottingham Score Mitotic Count","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubulin formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer. The Nottingham Score is a factor in determining the Nottingham Prognostic Index._definition pending","longName":"2431279v1.0:2431222v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2431279","version":"1","preferredName":"Nottingham Score","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubulin formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer. The Nottingham Score is a factor in determining the Nottingham Prognostic Index.","longName":"C25595","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nottingham Score","conceptCode":"C25595","definition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer. The Nottingham Score is a factor in determining the Nottingham Prognostic Index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF1C9-10BC-3A91-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431222","version":"1","preferredName":"Mitotic Count","preferredDefinition":"definition pending","longName":"C47864","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Count","conceptCode":"C47864","definition":"The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE31E-478E-3314-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DE011A-1BE1-40A6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2432057","version":"2","preferredName":"Mitotic Count Score","preferredDefinition":"The number of mitoses identified under the microscope in tumors. It is one of the parameters that determine the grade of malignant tumors. The method of counting varies, according to the specific tumor examined. Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"MIT_CT_SC","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":"less than 10 mitoses per 10 high HPF (25X objective) or 0 to 5 mitoses per 10 HPF (40X objective)","ValueMeaning":{"publicId":"2577183","version":"1","preferredName":"less than 10 mitoses per 10 high HPF (25X objective) or 0 to 5 mitoses per 10 HPF (40X objective)","longName":"2577183","preferredDefinition":"For a 25X objective with a field area of 0.274 mm squared: a score of 1 indicates less than 10 mitoses per 10 high power feilds. For a 40X objective with a field area of 0.152 mm squared: a score of 1 indicates 0 to 5 mitoses per 10 high power fields power fields.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA8C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-29","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-29","modifiedBy":"CROWLEYR","dateModified":"2005-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP Cancer Protocols","id":"44DC1EB9-7DDA-316E-E044-0003BA3F9857","beginDate":"2005-11-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-29","modifiedBy":"ONEDATA","dateModified":"2008-01-29","deletedIndicator":"No"},{"value":"2","valueDescription":"10-20 mitoses per 10 high power fields (25X objective) or  6 to 10 mitoses per 10 high power fields (40X objective)","ValueMeaning":{"publicId":"2577184","version":"1","preferredName":"10-20 mitoses per 10 high power fields (25X objective) or  6 to 10 mitoses per 10 high power fields (40X objective)","longName":"2577184","preferredDefinition":"For a 25X objective with a field area of 0.274 mm squared: a score of 2 indicates 10-20 mitoses per 10 high power fields. For a 40X objective with a field area of 0.152 mm squared: a score of 2 indicates 6 to 10 mitoses per 10 high power fields.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-29","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-29","modifiedBy":"CROWLEYR","dateModified":"2005-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP Cancer Protocols","id":"44DC1EB9-7DE4-316E-E044-0003BA3F9857","beginDate":"2005-11-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-29","modifiedBy":"ONEDATA","dateModified":"2008-01-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Greater than 20 mitoses per 10 HPF (25X objective) or greater than 10 mitoses per 10 HPF (40X objective)","ValueMeaning":{"publicId":"2577185","version":"1","preferredName":"Greater than 20 mitoses per 10 HPF (25X objective) or greater than 10 mitoses per 10 HPF (40X objective)","longName":"2577185","preferredDefinition":"For a 25X objective with a field area of 0.274 mm squared: a score of 2 indicates 10-20 mitoses per 10 high power fields. For a 40X objective with a field area of 0.152 mm squared: a score of 2 indicates 6 to 10 mitoses per 10 high power fields.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA8E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-29","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-29","modifiedBy":"CROWLEYR","dateModified":"2005-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP Cancer Protocols","id":"44DC1EB9-7DEE-316E-E044-0003BA3F9857","beginDate":"2005-11-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-29","modifiedBy":"ONEDATA","dateModified":"2008-01-29","deletedIndicator":"No"},{"value":"U","valueDescription":"Not Stated Unknown","ValueMeaning":{"publicId":"3371381","version":"1","preferredName":"Not Stated Unknown","longName":"3371381","preferredDefinition":"Not provided or available.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B85BD33E-6B5D-07C2-E040-BB89AD430D59","latestVersionIndicator":"Yes","beginDate":"2012-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B85BD33E-6B76-07C2-E040-BB89AD430D59","beginDate":"2012-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-07","modifiedBy":"ONEDATA","dateModified":"2012-02-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2725289","version":"1","preferredName":"Mitotic Count Score","preferredDefinition":"The number of mitoses identified under the microscope in tumors. It is one of the parameters that determine the grade of malignant tumors. The method of counting varies, according to the specific tumor examined. Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C47864:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic Count","conceptCode":"C47864","definition":"The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44DC1EB9-7DB0-316E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-29","modifiedBy":"ONEDATA","dateModified":"2008-01-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44DC1EB9-7DC1-316E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-29","modifiedBy":"REEVESD","dateModified":"2012-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812731","version":"1","longName":"U Washington","context":"NCIP"},{"publicId":"2812732","version":"1","longName":"FES Study","context":"NCIP"},{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812734","version":"1","longName":"U Washington New CDEs","context":"NCIP"}]},{"publicId":"2534075","version":"1.2","longName":"caTISSUE CAE","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000562","version":"1","longName":"edu.pitt.cabig.cae.domain.breast","context":"NCIP"}]},{"publicId":"2857187","version":"1","longName":"CAP Cancer Checklists","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812063","version":"1","longName":"edu.upmc.opi.cabig.caties.cap.domain.breast","context":"NCIP"}]},{"publicId":"3461586","version":"1","longName":"BOLD:Breast Oncology Local Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461587","version":"1","longName":"Preoperative Elements","context":"NCIP"},{"publicId":"3461588","version":"1","longName":"General Elements","context":"NCIP"}]},{"publicId":"3886753","version":"1","longName":"General Elements","context":"BOLD","ClassificationSchemeItems":[{"publicId":"3902138","version":"1","longName":"General","context":"BOLD"}]},{"publicId":"3886755","version":"1","longName":"Preoperative Elements","context":"BOLD","ClassificationSchemeItems":[{"publicId":"3902140","version":"1","longName":"Preoperative","context":"BOLD"}]}],"AlternateNames":[{"name":"NottinghamHistologicGrade:mitoticCount","type":"UML Class:UML Attr","context":"NCIP"},{"name":"NottinghamHistopathologicGrade:mitoticCount","type":"UML Class:UML Attr","context":"NCIP"},{"name":"edu.pitt.cabig.cae.domain.breast.NottinghamHistologicGrade.mitoticCount","type":"UML Qualified Attr","context":"NCIP"},{"name":"edu.upmc.opi.cabig.caties.cap.domain.breast.NottinghamHistopathologicGrade.mitoticCount","type":"UML Qualified Attr","context":"NCIP"}],"ReferenceDocuments":[{"name":"Mitotic Count","type":"Preferred Question Text","description":"Mitotic Count","url":null,"context":"NCIP"}],"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A5F2708-8FF2-51C5-E050-BB89AD434FAF","latestVersionIndicator":"Yes","beginDate":"2008-01-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-16","modifiedBy":"TAYLORT","dateModified":"2017-08-25","changeDescription":"8/25/17 tt CDE removed from Microscopic Path CRF per Round 5 finalization task. Changed reg status to \"Application\", removed from NCI Standards context and Microscopic Path CSI.  Curated to support U Washington adoption of C3D for FES trial._Version2.1 to correct definition - ghd-12-16-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}